Praxis Precision Net Worth

Praxis Precision Net Worth Breakdown

  PRAX
The net worth of Praxis Precision Medicines is the difference between its total assets and liabilities. Praxis Precision's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Praxis Precision's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Praxis Precision's net worth can be used as a measure of its financial health and stability which can help investors to decide if Praxis Precision is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Praxis Precision Medicines stock.

Praxis Precision Net Worth Analysis

Praxis Precision's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Praxis Precision's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Praxis Precision's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Praxis Precision's net worth analysis. One common approach is to calculate Praxis Precision's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Praxis Precision's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Praxis Precision's net worth. This approach calculates the present value of Praxis Precision's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Praxis Precision's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Praxis Precision's net worth. This involves comparing Praxis Precision's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Praxis Precision's net worth relative to its peers.

Enterprise Value

1.22 Billion

52.668.11.2B1.2B29%1609%5%100%
To determine if Praxis Precision is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Praxis Precision's net worth research are outlined below:
Praxis Precision Med generated a negative expected return over the last 90 days
Praxis Precision Med has high historical volatility and very poor performance
Praxis Precision Med has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 2.45 M. Net Loss for the year was (123.28 M) with loss before overhead, payroll, taxes, and interest of (112.91 M).
Praxis Precision Medicines currently holds about 165.4 M in cash with (111.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.7.
Praxis Precision Med has a frail financial position based on the latest SEC disclosures
Over 100.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: Praxis Precision Medicines Issues Quarterly Earnings Results
Praxis Precision uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Praxis Precision Medicines. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Praxis Precision's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Know Praxis Precision's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Praxis Precision is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Praxis Precision Medicines backward and forwards among themselves. Praxis Precision's institutional investor refers to the entity that pools money to purchase Praxis Precision's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Adage Capital Partners Gp Llc2024-12-31
605 K
Assenagon Asset Management Sa2024-12-31
559.1 K
Point72 Asset Management, L.p.2024-12-31
521.3 K
Verition Fund Managegment, Llc2024-12-31
464.5 K
Geode Capital Management, Llc2024-12-31
406.7 K
Franklin Resources Inc2024-12-31
389.8 K
Cibc Global Asset Management Inc2024-12-31
366.8 K
Baker Bros Advisors Lp2024-12-31
331.5 K
Nuveen Asset Management, Llc2024-09-30
304.8 K
Cormorant Asset Management, Llc2024-12-31
1.7 M
Blackrock Inc2024-12-31
1.5 M
Note, although Praxis Precision's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Praxis Precision's market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 719.42 M.

Market Cap

1.45 Billion

100%

Project Praxis Precision's profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.38)(0.40)
Return On Capital Employed(0.45)(0.47)
Return On Assets(0.38)(0.40)
Return On Equity(0.41)(0.43)
When accessing Praxis Precision's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Praxis Precision's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Praxis Precision's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Praxis Precision's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Praxis Precision Medicines. Check Praxis Precision's Beneish M Score to see the likelihood of Praxis Precision's management manipulating its earnings.

Evaluate Praxis Precision's management efficiency

Praxis Precision Med has return on total asset (ROA) of (0.392) % which means that it has lost $0.392 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6434) %, meaning that it created substantial loss on money invested by shareholders. Praxis Precision's management efficiency ratios could be used to measure how well Praxis Precision manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.4 in 2025. Return On Capital Employed is likely to drop to -0.47 in 2025. At this time, Praxis Precision's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 108.3 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 3 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 24.88  23.63 
Tangible Book Value Per Share 24.88  23.63 
Enterprise Value Over EBITDA(5.82)(5.52)
Price Book Value Ratio 3.09  1.74 
Enterprise Value Multiple(5.82)(5.52)
Price Fair Value 3.09  1.74 
Enterprise Value1.2 B1.2 B
Evaluating the management effectiveness of Praxis Precision allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Praxis Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue
226.8201
Revenue
1.6 M
Quarterly Revenue Growth
(0.35)
Revenue Per Share
0.106
Return On Equity
(0.64)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Praxis Precision insiders, such as employees or executives, is commonly permitted as long as it does not rely on Praxis Precision's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Praxis Precision insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Praxis Precision Corporate Filings

8K
28th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
14th of February 2025
Other Reports
ViewVerify
5th of February 2025
Other Reports
ViewVerify
F4
14th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
Praxis Precision time-series forecasting models is one of many Praxis Precision's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Praxis Precision's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Praxis Precision Earnings per Share Projection vs Actual

Praxis Precision Corporate Management

Dr BCoFounder OfficerProfile
Timothy KellyCFO TreasurerProfile
Nicole SweenyChief OfficerProfile
Kelly McCueChief OfficerProfile
Alyssa WyantChief OfficerProfile
Megan SniecinskiChief OfficerProfile
Lauren MastrocolaVP OfficerProfile

Additional Tools for Praxis Stock Analysis

When running Praxis Precision's price analysis, check to measure Praxis Precision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Praxis Precision is operating at the current time. Most of Praxis Precision's value examination focuses on studying past and present price action to predict the probability of Praxis Precision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Praxis Precision's price. Additionally, you may evaluate how the addition of Praxis Precision to your portfolios can decrease your overall portfolio volatility.

Trending Assets

EWTX
Edgewise Therapeutics
26.17  -0.22  -0.83 
HCWB
HCW Biologics
0.38  0.01  2.70 
CGEM
Cullinan Oncology LLC
8.49  -0.12  -1.39 
ELYM
ELYM Old
0.00  0.00  0.00